Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02429063 · ClinicalTrials.gov registry record · NA
Light Therapy to Increase Energy in Adolescents and Young Adults Newly Diagnosed With Solid Tumors: A Pilot Study
A NA study of Neoplasms and Fatigue, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- NA
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT02429063: Completed NA study of Neoplasms and Fatigue, sponsored by St. Jude Children's Research Hospital.
NCT02429063 is a NA study of Neoplasms and Fatigue that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 55 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02429063, a NA study of Neoplasms and Fatigue, has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
Fatigue is one of the most consistent and distressing symptoms reported by pediatric oncology patients. The investigators' work has demonstrated that in the period from diagnosis through the initial 8 weeks of treatment, adolescents and young adults with solid tumors experience substantial fatigue that is not related to sleep disruption. Fatigue can contribute to many adverse outcomes including poor treatment adherence, reduced social activities, depressive symptoms, behavior problems, and poorer quality of life. Unfortunately, no definitive intervention to reduce fatigue has been developed for pediatric oncology patients. Investigators propose a study to estimate the feasibility and acceptability of bright light therapy as an intervention to decrease fatigue in adolescents and young adults who are newly diagnosed and receiving treatment for solid tumors, including lymphoma.
Primary Outcome
Estimate the rates of consent to a BWL intervention, compared to DRL in adolescent/young adult solid tumor and lymphoma patients.
Interventions
- OTHER Bright White Light
- OTHER Dim Red Light
Study Locations (1)
Tennessee
- St . Jude Children's Research Hospital - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2015-07-17 |
| Est. Completion | 2022-05-03 |
| Phase | NA |
What the finished NCT02429063 record still lists
NCT02429063 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Bright White Light is the first listed.
NCT02429063 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT02429063 about?
NCT02429063 is a clinical study titled "Light Therapy to Increase Energy in Adolescents and Young Adults Newly Diagnosed With Solid Tumors: A Pilot Study". Fatigue is one of the most consistent and distressing symptoms reported by pediatric oncology patients. The investigators' work has demonstrated that in the period from diagnosis through the initial 8 weeks of treatment, adolescents and young adults with solid tumors experience substantial fatigue t...
What is the current status of trial NCT02429063?
This trial is currently completed. It is a NA study. The enrollment target is 55 participants. The study started on 2015-07-17. Estimated completion is 2022-05-03.
What conditions does trial NCT02429063 study?
This clinical trial studies the following conditions: Neoplasms, Fatigue.
What interventions are being tested in trial NCT02429063?
The interventions under investigation include: Bright White Light (OTHER), Dim Red Light (OTHER).
Who is sponsoring clinical trial NCT02429063?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02429063 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02429063's enrollment target sits among peer trials
55 101st of 158 higher than 58 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Endometrial Cell Collection With the PadKit
RECRUITING · NA
-
Serious Gaming for Chemotherapy-induced Nausea and Vomiting
RECRUITING · NA
-
Biennial CEM in Women With a Personal History of Breast Cancer
RECRUITING · NA
-
LITT Followed by Hypofractionated RT for Recurrent Gliomas
RECRUITING · NA
-
Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy
RECRUITING · NA
-
Screening Strategies Among High-risk Populations for Anal Cancer
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI